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Summary Non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) differ significantly in their clinical response to
topoisomerase lla (topo-lla)-directed drugs, such as etoposide and teniposide, as NSCLC is virtually insensitive to single-agent therapy, while
SCLC responds in two-thirds of cases. Preclinical studies have indicated that resistance to topo-lla drugs depends on topo-lIa content and/or
activity, the altered-topo-l1 multidrug resistance phenotype (at-MDR) and/or one of two different drug efflux pumps, P-glycoprotein (P-gp) and
the multidrug resistance protein (MRP). Immunohistochemical analysis on paraffin-embedded tissue from 27 cases of untreated NSCLC and
29 cases of untreated SCLC (of which additional tumour biopsies after treatment with topo-lla-directed drugs were available in ten cases)
yielded the following results: NSCLC had significantly less topo-lla than SCLC (P< 0.0001), as only 5 out of 27 NSCLC cases had > 5%
positive cells compared with 28 out of 29 SCLC, and 0 out of 27 NSCLC had > 25% positive cells compared with 26 out of 29 SCLC. P-gp was
detected in > 5% of cells in only 3 out of 27 NSCLC and in 6 out of 29 SCLC, and MRP in 5 out of 27 of NSCLC and 9 out of 29 SCLC. After
treatment of patients with SCLC with either etoposide or teniposide, which are topo-lla-directed drugs, there was an increase in MRP
(P< 0.1) and P-gp (P< 0.05) positivity, while topo-lla decreased (P< 0.05). In conclusion, the majordifference between untreated NSCLC and
SCLC was in topo-lla content. In the small series of ten patients treated for SCLC, all three MDR phenotypes appeared to increase.
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The treatment oflung cancer depends on whether the tumour has a
small-cell (SCLC) or non-small-cell (NSCLC) histology. SCLC
tumours are initially sensitive to drugs such as etoposide, which
acts on the nuclear enzyme DNA topoisomerase Ila (topo-IlIa) by
freezing an enzyme-DNA cleavable complex and thereby creating
DNA breaks, eventually leading to cell death. Such DNA-
damaging drugs are termed topo-II poisons as they convert an
essential enzyme to a lethal one (Chen and Liu, 1994). Despite
initial response rates of 70-80%, patients with SCLC usually
relapse with a clinically drug-resistant tumour, and the 2-year
survival is only approximately 5% (Hansen, 1992). Extensive
experimental research has documented the existence of several
cellular resistance mechanisms towards topo-LI poisons such as
etoposide, namely either a reduction and/or mutation in the
enzyme itself, called the altered topoisomerase 11 multidrug resis-
tance phenotype (at-MDR) (Pommier et al, 1986; Danks et al,
1988), or two well-characterized drug efflux pumps, P-glycopro-
tein (P-gp) (Borst et al, 1993) and MRP (Cole et al, 1992), both of
which have been shown in transfection studies to be sufficient to
confer resistance. The aim of the present study was to study the
expression of these three factors, topo-IIa, P-gp and MRP, in the
different histological types oflung cancer and in addition to inves-
tigate whether changes in their incidence occurred in SCLC after
treatment with etoposide or teniposide.
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MATERIALS AND METHODS
Patient biopsies
Nine consecutive cases of each of the main subtypes of NSCLC
[i.e. nine squamous cell carcinoma (SCC), nine adenocarcinoma
(AC), nine large-cell carcinoma (LC)] obtained by surgical resec-
tion and 29 cases of SCLC obtained by endobronchial biopsy or
from mediastinal lymph nodes were examined. All tumour tissue
was archival and had been formalin fixed for various time periods
before being paraffin embedded. The SCLC patients had a mean
age of 57 years, an equal male-female ratio and a mean survival
after treatment of 13.4 months. Complete and partial responses
were obtained in ten and eight patients, respectively, yielding a
total response rate of 62%. In 10 of the 29 SCLC cases, archival
tumour tissue was available after treatment with regimens that
included either etoposide or teniposide.
Immunohistochemistry
Monoclonal antibodies towards topo-Ila (KiS1) (Boege et al, 1995)
were a gift from Professor Kreipe, University of Wurzburg,
Germany, as well as being purchased from Boehringer Mannheim,
Germany. Antibodies towards P-gp (JSB-1) (Broxterman et al,
1989) were purchased from Sanbio, The Netherlands. Antibodies
towards MRP (MRPrl) (Flens et al, 1994) were a gift from
ProfessorR Scheper, Free University, Amsterdam, The Netherlands.
Paraffin sections (5 ,um) were deparaffinated in coconut oil at
60°C for 20 min and hydrated through ethanol-water dilutions.
Antigen retrieval was performed by treatment in a microwave oven
for 2 x 5 min in citrate buffer at 700 W. Endogenous peroxidase
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Table 1 Twenty-nine cases of pretreatment SCLC analysed for proportion
of tumour cells positive fortopo-Ila, P-gp and MRP
0% 0-5% 6-25% 26-50% > 50%
Topo-lla 1 0 2 15 11
P-gp 20 3 4 1 1
MRP 19 1 2 3 4
Figure 1 Topo-lla in SCLC demonstrating a strong nuclear localization.
Primary magnification x 250
Figure 2 Topo-lla in NSCLC (adenocarcinoma) showing only a few positive
cells, particularly compared with SCLC (Figure 1). Note heavily stained
mitotic figure (arrow). Primary magnification x 250
was blocked by 3% hydrogen peroxide for 5 min followed by 5 min
in Tris-buffered saline (TBS: 50 mm Tris, 150 mM sodium chloride,
pH 7.6). After a further incubation with 1% TBS-bovine serum
albumin (BSA) for 10 min, sections were incubated overnight in a
humidified chamber at 4°C with primary antibody diluted in 0.25%
TBS-BSA at the following concentrations: MRPrl at 1:50, JSB-1
at 1:300 and KiSl at 1:10 000. After three 5-min washes in TBS,
detection of the primary antibody was performed with the ABC
duet kit from Dako (Ballerup, Denmark) according to the manufac-
turer's instructions. 3-Amino-9-ethylcarbazole in 0.05 M buffered
acetic acid (pH 5.0) was used as chromogen.
As a positive control, human small-cell H69/VP cells were
formalin fixed, spun down into a pellet and paraffin embedded.
H69NVP cells overexpress both P-gp and MRP in low to moderate
degrees (Brock et al, 1995). Furthermore, they have an extra-
nuclear localization oftopo-IlIa, which is useful as a specific posi-
tive control (Wessel et al, 1997). As negative controls, wild-type
H69 cells, which do not express P-gp or MRP and which have a
nuclear localization of topo-IIa, were used. These control cells
together with negative controls with omission ofprimary antibody
were used in each staining reaction.
Table 2 Twenty-seven cases of pretreatment NSCLC (nine SCC, nine AC,
nine LC) analysed for proportion of tumour cells positive for topo-lla, P-gp
and MRP
0% 1-5% 6-25% 26-50% >50%
SCC
Topo-lla 0 5 4 0 0
P-gp 4 2 1 2 0
MRP 2 2 1 0 4
AC
Topo-lkla 1 8 0 0 0
P-gp 7 2 0 0 0
MRP 8 1 0 0 0
LC
Topo-lla 1 7 1 0 0
P-gp 6 3 0 0 0
MRP 8 1 0 0 0
NSCLC (total)
Topo-llaa 2 20 5 0 0
P-gp 17 7 1 2 0
MRP 18 4 1 0 4
aProportion of topo-lla-positive tumour cells is significantly lower than in
SCLC (see Table I) (P< 0.0001, Mann-Whitney test).
Stained sections were twice evaulated blindly by two partici-
pants (JK, MSe) and the percentage of positive tumour cells
collected by class as 0, > 0-5%, 6-25%, 26-50%, > 51% from
several fields depending on the size of the biopsy. Intraobserver
and interobserver variation was < 10% and never more than one
step. In these few cases of minor disagreement, a consensus was
reached before the code was broken. Intensity of the staining
reaction was not evaluated.
Statistics
The Mann-Whitney sum rank test was used in the statistical
analysis comparing scores of samples from SCLC and NSCLC.
Analyses on sequential SCLC biopsies were performed using
Wilcoxon's matched-pairs signed-rank sum test.
RESULTS
Topo-Illa
The topo-Iloc immunostaining was seen in a mainly nuclear local-
ization as well as a chromosomal localization in mitosis (Figures 1
and 2). As shown when comparing Tables 1 and 2, there was a
marked and significant (P < 0.0001) difference in the proportion of
tumour cells stained in SCLC vs NSCLC, for which 5 out of 27
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Figure 3 P-gp in SCLC demonstrating a mainly punctate 'Golgi' stain in
tumour cells, although a membraneous stain is also seen. Primary
magnification x 250
NSCLC cases had > 5% positive cells compared with 28 out of 29
SCLC, and 0 out of27 NSCLC had > 25% positive cells compared
with 26 out of 29 SCLC. In the series of pre- and post-treatment
SCLC specimens, a decrease was observed in seven out often cases
(P < 0.05) (Table 3). Topo-IIax was not observed in an extranuclear-
only localization, apossible resistance mechanism due to loss ofthe
enzyme's nuclear localization signal (Harker et al, 1995; Mirski
and Cole, 1995; Wessel et al, 1997), eitherbefore oraftertreatment.
Topo-IIax was only rarely observed in non-malignant cells in
lymphoid tissue or in basal bronchial epithelial cells.
P-gp
The immunostaining for P-gp was mostly seen in a punctate
'Golgi-like' pattern in tumour cells (Figure 3). However, in areas
with high staining intensity, a plasma membrane reaction was also
seen. An intracellular progression in sublines of increasing resis-
tance from a punctate to a membraneous staining reaction of P-gp
by the JSB-1 antibody was described in Broxterman et al (1989).
The incidence of P-gp was equal in untreated NSCLC and SCLC
(Tables 1 and 2) as it was detected in > 5% ofcells in only 3 out of
27 NSCLC and in 6 out of 29 SCLC. An increase in its frequency
was observed in six out of ten SCLC patients after treatment
(P < 0.05), being marked in two cases with increases from 0% to
above 50% of tumour cells positive (Table 3). In non-malignant
tissue, P-gp was often observed in superficial bronchial epithelium
and in a few cases ofNSCLC also in endothelial cells.
MRP
MRP was also found in roughly the same low proportion of
untreated NSCLC and SCLC cells, namely in 5 out of27 and 9 out
of 29 cases with > 5% positive tumour cells respectively (Tables 1
and 2). In NSCLC subtypes, high MRP expression was noted in
SCC (Table 2). In tumour cells, MRP exhibited a membraneous
stain. In non-malignant cells, MRP was often seen in superficial
bronchial epithelium, however, in contrast to P-gp, MRP was also
commonly observed in macrophages and scattered lymphocytes
(Figure 4), in agreement with a study using mRNA in situ
hybridization (Thomas et al, 1994). In SCLC, after treatment, an
increase in the proportion of positive cells was observed in four
Note: . -. X=. -.: .A
Figure 4 MRP in SCLC showing a positive reaction in stroma cells only.
Note positive stain in macrophages evidenced by colocalization of coal dust
(arrows). Primary magnification x 250
Table 3 Analysis of biopsies from ten SCLC patients before and after
treatment with either etoposide or teniposide for expression of topo-Ila, P-gp
and MRP
Patient no. Topo-lla P-gp MRP
Before After Before After Before After
1 3 2 2 4 0 3
2 4 3 0 4 2 2
3 4 4 0 4 0 2
4 3 4 0 0 0 2
5 4 2 0 0 0 1
6 .3 2 0 0 0 0
7 3 1 0 2 0 0
8 4 3 0 1 0 0
9 4 3 0 0 0 0
10 3 3 0 1 3 2
0, 0% positive tumour cells; 1, 1-5% positive tumour cells; 2, 6-25% positive
tumour cells; 3, 26-50% positive tumour cells; 4, >50% positive tumour cells.
Using Wilcoxon matched-pairs signed-rank sum test, the difference before
and after treatment in topo-Ila expression was significant at P<0.05, P-gp at
P<0.05 and MRPat P<0.1.
out of ten cases and a decrease in one out of ten cases (P < 0.1),
thus fewer and less pronounced changes than for P-gp.
DISCUSSION
Treatment of patients with SCLC by regimens containing a topo-
IIa-directed drug such as etoposide is now considered as standard
therapy, while NSCLC tumours are much less responsive to such
drugs. Although this marked difference in clinical response could
be due to a variety of causes, it appears reasonable to investigate
factors that are known to affect cellular sensitivity in preclinical
assays. With respect to drugs such as etoposide, there are now
three well-defined cellular multidrug resistance (MDR) mecha-
nisms, namely either drug efflux due to one of two plasma
membrane pumps, P-gp and MRP, which result in a decrease in
intracellular steady-state drug concentrations (Cole et al, 1992;
Borst et al, 1993), or changes in their drug target topo-IIa, namely
at-MDR (Pommier et al, 1986; Danks et al, 1988). The latter,
which was first described in a SCLC cell line by de Jong et al
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(1990), usually exists as adown-regulation ofenzyme amount, but
can also be due to mutations leading to a decreased drug sensi-
tivity. There now also exist well-defined monoclonal antibodies
that are able to detect each of these proteins in formalin-fixed
paraffin-embedded tissue. Obviously, detection of a protein does
not prove its functional ability, and phenomena such as mutations
andphosphorylation are known toinfluence theircatalytic activity.
However, a vast amount of preclinical data also supports the
notion that, within broad limits, an increase in protein content
entails an increase in functional ability. Further, comparison of
immunocytochemistry, Western blot andcatalytic activity oftopo-
Ila yielded a high correlation in a panel of NSCLC cell lines
(Yamazaki et al, 1996). The appropriate method of detection of
these drug resistance markers has been the subject ofconsiderable
debate (Broxterman et al, 1996), and it is recommended to use two
different assays, such as RT-PCR for specificity and quantification
and immunohistochemistry for localization (Beck et al, 1996).
This is not possible in a retrospective study on small tissue
samples, such as the present study, as there is too little extractable
mRNA in the paraffin-embedded sections (not shown). Another,
more troubling problem in the use of sensitive mRNA detection
techniques is the existence of P-gp and MRP proteins in normal
tissue, such as bronchial epithelium, andespecially the very strong
positivity for MRP seen in macrophages (Figure 4), where the
inclusion of a few such cells would be enough to skew a whole
tumour sample. In this respect, a mRNA and/or catalytic assay for
topo-Ila should be more dependable as this protein is, forpractical
purposes, only found in tumour tissue.
Both P-gp and MRP have been detected in SCLC and NSCLC,
although their clinical importance is still undecided (Volm et al,
1991; Holzmayer et al, 1992; Segawa et al, 1993; Tabata et al,
1993; Abe et al, 1994; Oberli-Schrammli et al, 1994; Peoch et al,
1994; Thomas et al, 1994; Ota et al, 1995; Sugarawa et al, 1995;
Beer et al, 1996; Chuman et al, 1996; Giaccone et al, 1996;
Narasaki et al, 1996; Nooter et al, 1996; Stammler et al, 1996). In
the present study, theirincidence was equal in untreated SCLC and
NSCLC (Tables 1 and 2), indicating that these drug efflux pumps
are not themselves responsible for the very different sensitivities
to etoposide in these two diseases. However, when analysing their
frequency in subtypes of NSCLC, it is interesting that both our
(Table II) and a previous study (Ota et al, 1995) detected an
increased level of MRP in SCC relative to other histological
subtypes. This was, however, not the case when an mRNA assay
was used (Sugarawa et al, 1995), a result which could be due to
admixture of MRP mRNA from macrophages and lymphocytes
(Thomas et al, 1994; Figure 4). The highly significant difference in
topo-Ila content between untreated SCLC and NSCLC (Tables 1
and 2) is therefore remarkable. Similar results using another topo-
IIa-directed antibody on formalin-fixed tissue from 17 SCLC and
24 NSCLC was recently described with a topo-IIa index (propor-
tion ofpositive cells per 1000 cells) of0.60 for SCLC and 0.31 for
NSCLC (Guinee et al, 1996). It would therefore be of interest to
study whether neuroendocrine AC, which has a better response to
topo-II drugs than AC, has increased topo-IIa. Interestingly, four
immunohistochemical studies on topo-IIa expression in breast
cancer (Kreipe et al, 1993; Tuccari et al, 1993; Hellemans et al,
1995; Jarvinen et al, 1996), two ofwhich used the same KiS1 anti-
body as in the present study (Kreipe et al, 1993; Jarvinen et al,
1996), all demonstrated a mean/median positive reaction in
10-20% of tumour cells, thus higher than what we observed for
NSCLC but much less than that for SCLC (Tables 1 and 2). This
correlates with the clinical observation that the response of breast
cancer to topo-IIa-targeted drugs is somewhere between that of
NSCLC and that ofSCLC.
The present study included ten SCLC patients for whom tumour
material before and after treatment was available. There was an
increase in both P-gp and MRP expression, the former being most
marked (Table 3). A similar increase in P-gp expression in SCLC
after treatment has previously been reported by Segawa et al
(1993) using immunohistochemistry and the C219 antibody, while
an increase in MRP expression or decrease in topo-IIa content
after treatment (Table 3) has not, to our knowledge, been reported
previously. It is quite possible that the lower topo-IIa expression
reflects a lower growth rate. However, whether a decrease in topo-
Ila is due to a decrease in the S/G2M fraction, to a specific down-
regulation of its promotor or to a post-translational modification,
the end result of a decrease in the specific target enzyme is the
same. A large body ofevidence using cell lines and yeast indicates
that it is the fluctuation ofenzyme level that is critical for cytotox-
icity (Webb et al, 1991; Nitiss et al, 1993). Further, when the tran-
scription factor E2F-1 is induced in stably transfected cells, thus
increasing the S-phase fraction, topo-IIa levels increase, as do
etoposide-induced DNA single-strand breaks and cytotoxicity
(Hofland et al, 1997). Thus cytotoxicity within a single cell line is
usually tightly linked to enzyme levels, the exceptions being drug-
induced mutations, which usually occur after there has been a
reduction in enzyme level, i.e. at higher levels of resistance.
Whether this link between enzyme content and and sensitivity is
also effective in clinical solid tumours is as yet unknown.
Thus, in conclusion, pretreatment levels of topo-IIa appear to
play a greater role than P-gp and MRP in determining the differen-
tial sensitivity of SCLC and NSCLC to drugs such as etoposide
and teniposide. Although only examined in a small series of ten
patients, the results indicate that all three known MDR phenotypes
increase after treatment for SCLC, with the changes in P-gp
expression being the most pronounced.
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AC, adenocarcinoma; at-MDR, altered topoisomerase II MDR;
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squamous cell carcinoma; SCLC, small-cell lung cancer; TBS,
tris-buffered saline; topo, topoisomerase
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